Oxygen and blood flow: Players in the pathogenesis of glaucoma

Molecular Vision

Volumn 14, Issue , 2008, Pages 224-233

  Mozaffarieh, Maneli ^a   Grieshaber, Matthias C ^a   Flammer, Josef ^a  

^a UNIVERSITY EYE CLINIC   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FREE RADICAL; NITRIC OXIDE; OXYGEN; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; AQUEOUS HUMOR; ASTROCYTE; ATHEROSCLEROSIS; AUTOREGULATION; BLOOD FLOW VELOCITY; CAPILLARY FLOW; CELL ACTIVATION; CELL STRESS; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DNA REPAIR; ENDOTHELIUM CELL; EYE BLOOD FLOW; GENICULATE NUCLEUS; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; ISCHEMIC OPTIC NEUROPATHY; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RECURRENT DISEASE; REGULATORY MECHANISM; REPERFUSION INJURY; RETINA BLOOD FLOW; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYMPTOM; TISSUE OXYGENATION; TRABECULAR MESHWORK; VASCULAR DISEASE;

EYE; GLAUCOMA; HUMANS; OXIDATIVE STRESS; OXYGEN; REGIONAL BLOOD FLOW;

EID: 38949099722     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Flammer J, Drance SM. Correlation between color vision scores and quantitative perimetry in suspected glaucoma. Arch Ophthalmol 1984; 102:38-9.
2. Flammer J, Orgul S, Costa VP. Orzalesi N, Kriegistein GK, Serra LM, Renard JP, Stefansson E. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res 2002; 21:359-93.
3. Izzotti A, Bagnis A, Sacca SC. The role of oxidative stress in glaucoma. Mutat Res 2006; 612:105-14.
4. Halliwell B. Reactive oxygen species in living systems: source, biochemistry, and role in human disease. Am J Med 1991; 91:14S-22S.
5. Freeman BA, Crapo JD. Biology of disease: free radicals and tissue injury. Lab Invest 1982; 47:412-26.
6. Halliwell B. Reactive species and antioxidants. Redox biology is a fundamental theme of aerobic life. Plant Physiol 2006; 141:312-22.
7. Haefliger IO, Flammer J, Beny JL, Luscher TF. Endothelium-dependent vasoactive modulation in the ophthalmic circulation. Prog Retin Eye Res 2001; 20:209-25.
8. Gugleta K, Zawinka C, Rickenbacher I, Kochkorov A, Katamay R, Flammer J, Orgul S. Analysis of retinal vasodilation after flicker light stimulation in relation to vasospastic propensity. Invest Ophthalmol Vis Sci 2006; 47:4034-41.
9. Grieshaber MC, Terhorst T, Flammer J. The pathogenesis of optic disc splinter haemorrhages: a new hypothesis. Acta Ophthalmol Scand 2006; 84:62-8.
10. Flammer J, Prunte C. [Ocular vasospasm. 1: Functional circulatory disorders in the visual system, a working hypothesis]. Klin Monatsbl Augenheilkd 1991; 198:411-2.
11. Flammer J, Orgul S. Optic nerve blood-flow abnormalities in glaucoma. Prog Retin Eye Res 1998; 17:267-89.
12. Haefliger IO, Dettmann E, Liu R, Meyer P, Prunte C, Messerli J, Flammer J. Potential role of nitric oxide and endothelin in the pathogenesis of glaucoma. Surv Ophthalmol 1999; 43 Suppl I:S51-8.
13. Orgul S, Cioffi GA, Bacon DR, Van Buskirk EM. An endothelin-1-induced model of chronic optic nerve ischemia in rhesus monkeys. J Glaucoma 1996; 5:135-8.
14. Strenn K, Matulla B, Wolzt M, Findl O, Bekes MC, Lamsfuss U, Goselli U, Rainer G, Menapace R, Eichler HG, Schmetterer L. Reversal of endothelin-1-induced ocular hemodynamic effects by low-dose nifedipine in humans. Clin Pharmacol Ther 1998; 63:54-63.
15. Haufschild T, Shaw SG, Kesselring J, Flammer J. Increased endothelin-1 plasma levels in patients with multiple sclerosis. J Neuroophthalmol 2001; 21:37-8.
16. Haufschild T, Prunte C, Messerli J, Flammer J. Increased endothelin-1 plasma level in young adults with retinal vascular occlusive diseases. Klin Monatsbl Augenheilkd 2004; 221:357-9.
17. Haufschild T, Shaw SG, Kaiser HJ, Flammer J. Transient raise of endothelin-1 plasma level and reduction of ocular blood flow in a patient with optic neuritis. Ophthalmologica. 2003; 217:451-3.
18. Pache M, Kaiser HJ, Akhalbedashvili N, Lienert C, Dubler B, Kappos L, Flammer J. Extraocular blood flow and endothelin-1 plasma levels in patients with multiple sclerosis. Eur Neurol 2003; 49:164-8.
19. Pache M, Kaiser HJ, Haufschild T, Lubeck P, Flammer J. Increased endothelin-1 plasma levels in giant cell arteritis: a report on four patients. Am J Ophthalmol 2002; 133:160-2.
20. Flammer J, Pache M, Resink T. Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog Retin Eye Res 2001; 20:319-49.
21. Gasser P. [Raynaud's syndrome: diagnosis and therapy in general practice]. Schweiz Rundsch Med Prax 1989; 78:868-73.
22. Prunte-Glowazki A, Flammer J. [Ocular vasospasm. 4: Clinical examples]. Klin Monatsbl Augenheilkd 1991; 198:415-8.
23. Mocco J, Ransom ER, Komotar RJ, Mack WJ, Sergot PB, Albert SM, Connolly ES Jr. Racial differences in cerebral vasospasm: a systematic review of the literature. Neurosurgery 2006; 58:305-14.
24. Beltrame JF, Sasayama S, Maseri A. Racial heterogeneity in coronary artery vasomotor reactivity: differences between Japanese and Caucasian patients. J Am Coll Cardiol 1999; 33:1442-52.
25. Flammer J: Glaucoma. A guide for patients. An introduction for care providers. A quick reference. 3rd revised edition. Bern, Hogrefe and Huber Publishers, 2006.
26. Guthauser U, Flammer J, Mahler F. The relationship between digital and ocular vasospasm. Graefes Arch Clin Exp Ophthalmol 1988; 226:224-6.
27. Gasser P, Stumpfig D, Schotzau A, Ackermann-Liebrich U, Flammer J. Body mass index in glaucoma. J Glaucoma 1999; 8:8-11.
28. Teuchner B, Orgul S, Ulmer H, Haufschild T, Flammer J. Reduced thirst in patients with a vasospastic syndrome. Acta Ophthalmol Scand 2004; 82:738-40.
29. Orgul S, Kaiser HJ, Flammer J, Gasser P. Systemic blood pressure and capillary blood-cell velocity in glaucoma patients: a preliminary study. Eur J Ophthalmol 1995; 5:88-91.
30. Gasser P, Meienberg O. Finger microcirculation in classical migraine. A video-microscopic study of nailfold capillaries. Eur Neurol 1991; 31:168-71.
31. Wunderlich K, Zimmerman C, Gutmann H, Teuchner B, Flammer J, Drewe J. Vasospastic persons exhibit differential expression of ABC-transport proteins. Mol Vis 2003; 9:756-61.
32. Pache M, Krauchi K, Cajochen C, Wirz-Justice, A, Dubler R, Flammer J, Kaiser HJ. Cold feet and prolonged sleep-onset latency in vasospastic syndrome. Lancet 2001; 358:125-6.
33. Flammer J. [Innovative glaucoma therapy]. Ophthalmologe 2001; 98:923-4.
34. Kochkorov A, Gugleta K, Zawinka C, Katamay R, Flammer J, Orgul S. Short-term retinal vessel diameter variability in relation to the history of cold extremities. Invest Ophthalmol Vis Sci 2006;47:4026-33.
35. Gugleta K, Orgul S, Hasler PW, Picornell T, Gherghel D, Flammer J. Choroidal vascular reaction to hand-grip stress in subjects with vasospasm and its relevance in glaucoma. Invest Ophthalmol Vis Sci 2003; 44:1573-80.
36. Gugleta K, Kochkorov A, Katamay R, Zawinka C, Flammer J, Orgul S. On pulse-wave propagation in the ocular circulation. Invest Ophthalmol Vis Sci 2006; 47:4019-25.
37. Gherghel D, Orgul S, Dubler B, Lubeck P, Gugleta K, Flammer J. Is vascular regulation in the central retinal artery altered in persons with vasospasm? Arch Ophthalmol 1999; 117:1359-62.
38. Gherghel D, Orgul S, Gugleta K, Gekkieva M, Flammer J. Relationship between ocular perfusion pressure and retrobulbar blood flow in patients with glaucoma with progressive damage. Am J Ophthalmol 2000; 130:597-605.
39. Flammer J. [Glaucomatous optic neuropathy: a reperfusion injury]. Klin Monatsbl Augenheilkd 2001; 218:290-1.
40. Flammer J, Mozaffarieh M. What is the present pathogenetic concept of glaucomatous optic neuropathy? Surv Ophthalmol 2007; 52:S162-73.
41. Russell P, Johnson DH. Enzymes protective of oxidative damage present in all decades of life in the trabecular meshwork, as detected by two-dimensional gel electrophoresis protein maps. J Glaucoma 1996; 5:317-24.
42. Sacca SC, Izzotti A, Rossi P, Traverso C. Glaucomatous outflow pathway and oxidative stress. Exp Eye Res 2007; 84:389-99.
43. Ueda J, Wentz-Hunter K, Yue BY. Distribution of myocilin and extracellular matrix components in the juxtacanalicular tissue of human eyes. Invest Ophthalmol Vis Sci 2002; 43:1068-76.
44. Spector A, Garner WH. Hydrogen peroxide and human cataract. Exp Eye Res 1981; 33:673-81.
45. Rose RC, Richer SP, Bode AM. Ocular oxidants and antioxidant protection. Proc Soc Exp Biol Med 1998; 217:397-407.
46. Zhou L, Li Y, Yue BY. Oxidative stress affects cytoskeletal structure and cell-matrix interactions in cells from an ocular tissue: the trabecular meshwork. J Cell Physiol 1999; 180:182-9.
47. Li AF, Tane N, Roy S. Fibronectin overexpression inhibits trabecular meshwork cell monolayer permeability. Mol Vis 2004; 10:750-7.
48. Wentz-Hunter K, Shen X, Okazaki K, Tanihara H, Yue BY. Overexpression of myocilin in cultured human trabecular meshwork cells. Exp Cell Res 2004; 297:39-48.
49. Kahn MG, Giblin FJ, Epstein DL. Glutathione in calf trabecular meshwork and its relation to aqueous humor outflow facility. Invest Ophthalmol Vis Sci 1983; 24:1283-7.
50. Izzotti A, Sacca SC, Cartiglia C, De Flora S. Oxidative deoxyribonucleic acid damage in the eyes of glaucoma patients. Am J Med 2003; 114:638-46.
51. Sacca SC, Pascotto A, Camicione P, Capris P, Izzotti A. Oxidative DNA damage in the human trabecular meshwork: clinical correlation in patients with primary open-angle glaucoma. Arch Ophthalmol 2005; 123:458-63.
52. Ferreira SM, Lemer SF, Brunzini R, Evelson PA, Llesuy SF. Oxidative stress markers in aqueous humor of glaucoma patients. Am J Ophthalmol 2004; 137:62-9.
53. Gherghel D, Griffiths HR, Hilton EJ, Cunliffe IA, Hosking SL. Systemic reduction in glutathione levels occurs in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2005; 46:877-83.
54. Yang J, Tezel G, Patil RV, Romano C, Wax MB. Serum autoantibody against glutathione S-transferase in patients with glaucoma. Invest Ophthalmol Vis Sci 2001; 42:1273-6.
55. Tamm ER, Russell P, Johnson DH, Watigorsky J. Human and monkey trabecular meshwork accumulate alpha B-crystallin in response to heat shock and oxidative stress. Invest Ophthalmol Vis Sci 1996; 37:2402-13.
56. Iwaki T, Iwaki A, Tateishi J, Goldman JE. Sense and antisense modification of glial alpha B-crystallin production results in alterations of stress fiber formation and thermoresistance. J Cell Biol 1994; 125:1385-93.
57. Mehlen P, Preville X, Chareyron P, Briolay J, Klemenz R, Arrigo AP. Constitutive expression of human hsp27, Drosophila hsp27, or human alpha B-crystallin confers resistance to TNF- and oxidative stress-induced cytotoxicity in stably transfected murine L929 fibroblasts. J Immunol 1995; 154:363-74.
58. Tezel G, Wax MB. Hypoxia-inducible factor 1alpha in the glaucomatous retina and optic nerve head. Arch Ophthalmol 2004; 122:1348-56.
59. Pillunat LE, Larsson LI, European and Canadian Latanoprost Study Group. Intraocular pressure after replacement of current dual therapy with latanoprost monotherapy in patients with open angle glaucoma. Br J Ophthalmol 2003; 87:1492-6.
60. Satilmis M, Orgul S, Doubler B, Flammer J. Rate of progression of glaucoma correlates with retrobulbar circulation and intraocular pressure. Am J Ophthalmol 2003; 135:664-9.
61. Weber J, Koll W, Krieglstein GK. Intraocular pressure and visual field decay in chronic glaucoma. Ger J Ophthalmol 1993; 2:165-9.
62. Flammer J, Eppler E, Niesel P, [Quantitative perimetry in the glaucoma patient without local visual field defects]. Graefes Arch Clin Exp Ophthalmol 1982; 219:92-4.
63. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000; 9:134-42.
64. Neufeld AH, Hernandez MR, Gonzalez M. Nitric oxide-synthase in the human glaucomatous optic nerve head. Arch Ophthalmol 1997; 115:497-503.
65. Mojon DS, Hess CW, Goldblum D, Fleischhauer J, Koerner F, Bassetti C, Mathis J. High prevalence of glaucoma in patients with sleep apnea syndrome. Ophthalmology 1999; 106:1009-12.
66. Drance SM. The visual field of low tension glaucoma and shock-induced optic neuropathy. Arch Ophthalmol 1977; 95:1359-61.
67. Moenkemann H, Flammer J, Wunderlich K, Breivohl W, Schild HH, Golubnitschaja O. Increased DNA breaks and up-regulation of both G(1) and G(2) checkpoint genes p2l(WAF1/CIP1) and 14-3-3 sigma in circulating leukocytes of glaucoma patients and vasospastic individuals. Amino Acids 2005; 28:199-205.
68. Golubnitschaja-Labudova O, Liu R, Decker C, Zhu P, Haefliger IO, Flammer J. Altered gene expression in lymphocytes of patients with normal-tension glaucoma. Curr Eye Res 2000; 21:867-76.
69. Emre M, Orgul S, Haufschild T, Shaw SG, Flammer J. Increased plasma endothelin-1 levels in patients with progressive open angle glaucoma. Br J Ophthalmol 2005; 89:60-3.
70. Golubnitschaja O, Yeghiazaryan K, Liu R, Monkemann H, Leppert D, Schild H, Haefliger IO, Flammer J: Increased expression of matrix metalloproteinases in mononuclear blood cells of normal-tension glaucoma patients. J Glaucoma 2004; 13:66-72.
71. Wunderlich K, Golubnitschaja O, Pache M, Eberle AN, Flammer J. Increased plasma levels of 20S proteasome alpha-subunit in glaucoma patients: an observational pilot study. Mol Vis 2002; 8:431-5.
72. Mozaffarieh M, Flammer J. Is There More to Glaucoma Treatment Than Lowering IOP? Surv Ophthalmol 2007; 52-S174-9.
73. Mozaffarieh M, Flammer J. A novel perspective on natural therapeutic approaches in glaucoma therapy. Expert Opin Emerg Drugs 2007; 12:195-8.
74. Mozaffarieh M, Grieshaber MC, Orgel S, Flammer J. The potential value of antioxidative treatment in glaucoma. Surv Ophthalmol (2008), in press.
75. Ritch R. Neuroprotection: is it already applicable to glaucoma therapy? Curr Opin Ophthalmol 2000; 11:78-84.
76. Ritch R. Complementary therapy for the treatment of glaucoma: a perspective. Ophthalmol Clin North Am 2005; 18:597-609.